SANGUINE
LIVE

Serial Number

98097005

Owner

Sanguine Biosciences, Inc.

Attorney

Elizabeth Oliner

Filing Date

Jul 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

SANGUINE Trademark

Serial Number: 98097005 • Registration: 7638314

SANGUINE is a trademark filed by Sanguine Biosciences, Inc. on July 21, 2023. The trademark is classified under Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Sanguine Biosciences, Inc. (8 trademarks)

400 W Cummings Park, Suite 3050
Woburn, MA 01801

Entity Type: 03

Trademark Details

Filing Date

July 21, 2023

Registration Date

January 7, 2025

Published for Opposition

November 19, 2024

Goods & Services

Research laboratory analysis of biospecimens for cell analysis assays, cell count, immunophenotyping, and HLA typing for use in infectious disease research. Research laboratory services providing biospecimen analysis, cell analysis assays, cell count, immunophenotyping, and HLA typing for use in infectious disease research. Compiling data for research purposes in the field of medical science and medical consultancy. Medical and scientific research in the fields of autoimmune diseases, genetic disorders, neurological disorders, oncology, infectious diseases, and immunology related to biomarker discovery and validation, drug discovery and development, diagnostics development, and translational applications. Providing an online searchable database in the field of autoimmune diseases, genetic disorders, neurological disorders, oncology, infectious diseases, immunology and health for scientific research purposes. Providing an online searchable database in the field of biospecimen and data collection for scientific research purposes. Providing information about medical research in the field of autoimmune diseases, genetic disorders, neurological disorders, oncology, infectious diseases, and immunology for purposes including biomarker discovery and validation, drug discovery and development, diagnostics development, and other translational applications. Providing information on the subject of scientific research in the field of biochemistry and biotechnology. Scientific laboratory services. Scientific research for medical purposes in the field of autoimmune diseases, genetic disorders, neurological disorders, oncology, infectious diseases, immunology, biomarker discovery and validation, drug discovery and development, diagnostics development, and translational applications. Scientific research in the field of autoimmune diseases, genetic disorders, neurological disorders, oncology, infectious diseases, oncology and health research. Providing biospecimen collection and data collection for scientific research purposes in the field of autoimmune diseases, genetic disorders, neurological disorders, oncology, infectious diseases, immunology, biomarker discovery and validation, drug discovery and development, diagnostics development, and translational applications

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 7, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 7, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 19, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 19, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 13, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 8, 2024 CNSA
RESTORE TO TEAS PLUS
Oct 8, 2024 RTTP
EXAMINER'S AMENDMENT ENTERED
Sep 26, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 26, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 26, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 26, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 29, 2024 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Aug 29, 2024 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jul 2, 2024 GNFN
FINAL REFUSAL E-MAILED
Jul 2, 2024 GNFR
FINAL REFUSAL WRITTEN
Jul 2, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 12, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 12, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 12, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 25, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 25, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 25, 2024 CNRT
REMOVED FROM TEAS PLUS
Mar 25, 2024 RFTP
ASSIGNED TO EXAMINER
Mar 25, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 21, 2023 NWOS
NEW APPLICATION ENTERED
Jul 25, 2023 NWAP